Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF FINANCIAL OFFICER | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,494 |
Ending reported balance
After 2026-02-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 5,332 · Balance 38,290 Row 2 · 2026-02-20 · Tax withholding · Disposed 2,876 · Balance 35,414 F1: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Row 3 · 2026-02-23 · Exercise / conversion · Acquired 6,688 · Balance 42,102 Row 4 · 2026-02-23 · Tax withholding · Disposed 3,608 · Balance 38,494 F2: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,995 |
Reported balance
After 2026-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-20 · Exercise / conversion · Disposed 5,332 · Balance 15,995 F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 36,357 |
Reported balance
After 2026-02-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-23 · Exercise / conversion · Disposed 6,688 · Balance 36,357 F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 506 | $34.20 | $17,305.20 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,394 F2 · shares: The reported disposition of 506 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 2,503 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · derivative · entry 7 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,005 Underlying: Common Stock · 2,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,025 | $34.94 | $35,813.50 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,511 F1 · shares: The reported disposition of 1,025 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.